



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2022 #1

January 6, 2023

## INSIDE:

New Resource on COVID-19 Vaccines and Blood Donation Available .....	2
NBDM Begins with News Release from the Blood Community — ADRP Develops NBDM Resources for Blood Centers.....	2
Results Reported of Randomized Trial of Convalescent/Vaccinated Plasma in High-risk Patients .....	3
REGULATORY NEWS....	4
RESEARCH IN BRIEF ....	5
December <i>Blood Bulletin</i> Published.....	6
Executive Compensation Survey Report Available .....	6
Television & Radio Versions of "Career in Blood" Recruitment Video Available.....	6
PEOPLE.....	7
BRIEFLY NOTED.....	7
COMPANY NEWS .....	8
CALENDAR.....	8
POSITIONS.....	8

## Provisions Impacting Blood Centers Included in Government Funding Bill

President Biden recently signed the [Consolidated Appropriations Act, 2023](#). The \$1.7 trillion package, which includes \$772.5 billion in nondefense discretionary funding and \$858 billion in defense spending, will fund the federal government for fiscal year 2023.

Within the legislation are multiple provisions of interest that impact community blood centers. These include:

- funding for the U.S. Food and Drug Administration (FDA) which increased by \$226 million over the 2022 funding level in order to support increased safety activities;
- increases in funding for the Centers for Disease Control & Prevention (CDC), the National Institutes of Health (NIH), and the Office of the Assistant Secretary of Preparedness and Response (ASPR), which includes BARDA. This funding aims to speed development of therapeutics, prevention measures, diagnostics, and increase public health activities with a focus on pandemic preparedness including countermeasures and fortifying the stockpile of supplies that may be necessary in emergencies such as a pandemic; and
- a provision that America's Blood Centers (ABC) worked on extensively on the Hill to increase coordination among federal agencies to support the nation's blood supply. The provision requires communication and collaboration between the government agencies and stakeholders including community blood centers.

The bill does not include the Verifying Accurate Leading-edge IVCT Development (VALID) Act which would have changed the way lab developed tests are regulated. ABC has previously expressed concern with the complexity and potential burden on blood centers that the VALID Act would establish and has worked with the congressional committees of jurisdiction to ensure they are aware of its potential impact on community blood centers. Though it is not included in this package, ABC anticipates Congress will continue to engage on this subject, requiring ongoing advocacy efforts. Updates will be provided to member blood centers as they become available. Please contact ABC Senior Director of Federal Government [Affairs Diane Calmus, JD](#) with questions.

(Source: [MCN 23-003](#), 1/3/23) ◆



## New Resource on COVID-19 Vaccines and Blood Donation Available

America's Blood Centers (ABC) has developed a new [resource](#) for member blood centers titled "Frequently Asked Questions [FAQ]: COVID Vaccines and Blood Donation." The FAQ is meant to assist member blood centers in answering questions on this topic. The resource can be used both internally and externally, including on websites and social media. Member blood centers can find talking points on this issue [here](#). Additionally, ABC will continue to develop more resources on this topic. These include an upcoming *Blood Bulletin* on directed donations that will be published by March 2023. Please let [us](#) know if you have any additional questions or comments.

(Source: [MCN 22-103](#), 12/29/22) ♦

## NBDM Begins with News Release from the Blood Community — ADRP Develops NBDM Resources for Blood Centers



America's Blood Centers (ABC), the Association for the Advancement of Blood & Biotherapies (AABB), and the American Red Cross have issued a [news release](#) kicking off the arrival of National Blood Donor Month (NBDM). In the release, the blood community thanks individuals for being blood donors. "We all owe America's blood donors a debt of gratitude for their selfless generosity," said ABC Chief Executive Officer Kate Fry, MBA, CAE, in the news release. "Everyone knows someone whose life has been changed through a blood transfusion. National Blood Donor Month is an opportunity to recognize the more than 7 million people who donate blood each year and encourage more people to become donors and help save lives."

people to become donors and help save lives."

The organizations also "applaud[ed] a recent action by the U.S. Food and Drug Administration to change its eligibility requirements for individuals that were previously deferred from donating blood because they lived, or were stationed, in certain countries outside of the U.S. in the 1980s and 1990s. The blood community welcomes back the hundreds of thousands of individuals now eligible to donate blood, includ[ing] many of our nation's veterans." Additionally, the blood community continued to "encourage[e] eligible Americans to donate blood in January and to make regular appointments to donate throughout the year."

ADRP, an international division of ABC, has created [resources](#) for blood centers to use throughout NBDM including:

- agnostic social media assets in English and Spanish with sample posts;
- newsletter drop-ins to use in communications efforts or to submit to partner groups;
- letter to the editor templates;
- op-ed templates;
- and an official NBDM logo.

(Source: Blood Community Joint [News Release](#), 1/4/23) ♦





## Results Reported of Randomized Trial of Convalescent/Vaccinated Plasma in High-risk Patients

Researchers in *Nature* [shared](#) their findings from a randomized, controlled clinical trial “with convalescent/vaccinated plasma in high-risk patients, including patients with cancer with severe COVID-19, [that sought to] analyz[e] the association between plasma therapy and the response of neutralizing antibody titers in plasma recipients.” The study included 134 patients segmented into four groups:

- “Group 1 (cancer): patients with pre-existing or concurrent hematological cancer and/or receiving active cancer therapy for any cancer (including chemotherapy, radiotherapy, and surgical treatments) within the past 24 months;
- Group 2 (immunosuppression): patients experiencing chronic immunosuppression, either pharmacological or due to underlying diseases not meeting group 1 criteria;
- Group 3 (lymphopenia/elevated D-dimers): patients aged >50 years and ≤75 years and not meeting group 1 or 2 criteria who had lymphopenia ( $<0.8 \times 10^9$  cells per liter) and/or D-dimers ( $>1 \mu\text{g ml}^{-1}$ ); [and]
- Group 4 (age >75 years): patients aged >75 years and not meeting group 1, 2 or 3 criteria.”

Enrollment took place from September 2020 to January 2022 as 68 were placed in the plasma arm and 66 in the control arm. The researchers stated that “[p]atients in the plasma cohort received at least one unit of ABO-compatible plasma, and 10 control patients crossed over to the plasma group at day 10 after randomization. Plasma donor eligibility required high titers of neutralizing antibody activity in a live virus neutralization assay (titers  $\geq 1:80$ ;  $<20$  percent of potential donors)...A clinical seven-point ordinal scale (7POS) was determined daily, which was defined as:

- not hospitalized, with resumption of normal activities;
- not hospitalized, but unable to resume normal activities;
- hospitalized, but not requiring supplemental oxygen;
- hospitalized and requiring supplemental oxygen;
- hospitalized and requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both;
- hospitalized and requiring extracorporeal membrane oxygenation, invasive mechanical ventilation, or both; and
- death.”

(continued on page 4)

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2023 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

### America’s Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Rita Reik

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

**Annual Subscription Rate: \$390**

Send subscription queries to

[memberservices@americasblood.org](mailto:memberservices@americasblood.org)

America’s Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).

### Results Reported of Randomized Trial of Convalescent/Vaccinated Plasma (continued from page 3)

The study found that “the median time from randomization to improvement of two points on the 7POS or live hospital discharge was 12.5 d (95 percent confidence interval (CI) = 10–17) in the plasma arm and 18 d (95 percent CI = 11–28) in the control arm (hazard ratio (HR) = 1.29; 95 percent CI = 0.86–1.93; log-rank P = 0.205). Pre-specified subgroup analyses revealed benefit in patients with cancer (group 1; n = 56). For patients with cancer, the median time to improvement was 13 d (95 percent CI = 7–14) for the plasma arm and 31 d (95 percent CI = 15–not available (NA)) for the control arm (HR = 2.50; 95 percent CI = 1.34–4.79; log-rank P = 0.003)...Overall, 27 patients died and no significant difference was seen for overall survival according to randomization (HR = 0.72; 95 percent CI = 0.33–1.55; log-rank P = 0.403). In the cancer group (group 1), improved overall survival was observed in the plasma arm compared with the control arm (HR = 0.28; 95 percent CI = 0.06–0.96; log-rank P = 0.042)...The time to discharge did not differ (HR = 1.28; 95 percent CI = 0.86–1.91; log-rank P = 0.217) in the overall study population (12.5 d (95 percent CI = 10–17) for the plasma arm versus 18 d (95 percent CI = 11–28) for the control arm)...In patients with cancer, the neutralizing activity did not increase over time in the absence of plasma therapy. In contrast, plasma therapy increased the neutralizing activity in patients with cancer who had higher levels on day 3/5 (group 1; 30.9 percent (IQR = 15.4–98.0) for the plasma arm compared with 8.8 percent (IQR = 3.5–46.3) for the control arm. The authors concluded that “[t]he results of this trial provide evidence that patients with cancer (group 1) who develop severe COVID-19 benefit from anti-SARS-CoV-2 plasma from convalescent/vaccinated donors and experience improved overall recovery... We found that in patients with cancer an increase in neutralizing antibodies was observed after plasma infusion, which further supports the restriction of the beneficial effects of plasma to patients with limited ability to react to the antigen with a humoral response... Given the limited available effective treatment options for patients with cancer and the favorable safety profile, convalescent/vaccinated plasma should be considered. Further confirmation of the findings is expected to come from other larger trials.”

**Citation:** Denkinger, C., Janssen, M., Schäkel, U. *et al.* “[Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.](#)” *Nature*. 2022. 💧

## REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) has issued an updated [communication](#) titled “Important Information for Blood Establishments and Transfusion Services Regarding Bacterial Contamination of Platelets for Transfusion.” The December 22<sup>nd</sup> agency communication aims “to inform blood establishments and transfusion services on the investigation of septic transfusion reactions from apheresis platelets contaminated with *Acinetobacter* species and certain other bacterial species seen in combination. Since 2018, FDA and the Centers for Disease Control and Prevention (CDC) have worked collaboratively to investigate these reports, including those described” in the communication. It updates the previous communications on this subject that were published in April 2019 and December 2021. The FDA stated in the communication that “it is important for blood establishments and transfusion services to continue to recognize the risk of bacterial contamination of platelets, including in bacterially tested and pathogen-reduced platelet components.” Since 2018, the agency is “aware of a total of seven septic transfusion reactions (from six total donations) involving either *Acinetobacter* spp., *Staphylococcus saprophyticus*, *Leclercia adecarboxylata*, or combinations thereof, where additional genetic testing of isolates by the CDC found with high probability that the organisms were related and had a potential common source. These cases occurred in multiple states, and the implicated components were subject to various bacterial risk mitigation strategies including bacterial culture and/or secondary rapid testing prior to release, or processing with an FDA-approved pathogen reduction device prior to transfusion. FDA also received additional reports of positive bacterial cultures during routine testing of units that were not transfused where the same organisms were also identified.”

(Source: FDA [Communication](#), 12/22/22) 💧



## RESEARCH IN BRIEF

**Capture the Imagination: An Incredible Case of Transfusion-Associated Graft-vs.-Host Disease.** A fictional *British Medical Journal* case [report](#) provides a novel approach to discuss transfusion-associated graft-vs-host disease (TaGVHD). The author describes the “case of non-lethal TaGVHD due to blood contamination of an open wound after a car accident [in which the] recipient inherit[ed] the ability of the donor to transform into an enormous green rage monster...The donor is Bruce Banner MD, PhD, the strongest ‘Avenger,’ [while the] recipient is Jennifer Walters, JD, ‘She-Hulk,’ [who works at a] high profile law firm, representing superhuman clients.” The report explains that “[t]he donor and recipient, his first cousin, share genetic factors that allow them to synthesize gamma radiation...They also share HLA haplotypes...Among the risk factors for TaGVHD, one is partial HLA similarity between the donor and host, [that] could give donor T cells increased ability to avoid the host immune system and engraft.” The author noted that “[p]atients with immunocompromising conditions are at higher risk for TaGVHD [and in] this case, the recipient received a lethal dose of gamma radiation, which could have weakened her T lymphocyte response enough to lead to engraftment.” Irradiation eliminates “engraftment potential of T lymphocytes.” The report explained that “[t]he 2020 British Committee for Standards in H[e]matology recommends at least 25 Gy of radiation...The ‘gamma’ produced endogenously within Dr. Banner [and transfused to] Ms. Walters could be modulating donor T cells, preventing fatal effects of TaGVHD.” Other “manifestations of TaGVHD of the recipient raises questions...In particular, why green rather than red or yellow? In TaGVHD, infiltration of the skin by engrafted donor T lymphocytes produces a diffuse, erythrodermic (red) rash.” The author noted that “Red Hulks have been described in case reports...Alternatively, TaGVHD disease of the liver could cause hepatic failure, giving rise to jaundice...Yellow Hulks have also been described in pre-prints...Ms. Walters [also] experiences reversible, stress induced muscular hypertrophy...One possibility is that the transfused blood contained cells with myogenic potential.” The author concluded that “[w]hile superheroes as blood and bone marrow donors capture the imagination, it is hoped that this case encourages normal humans to donate blood — allowing them to become the real heroes.”

**Citation:** Barrett, N.A. [She-Hulk: an incredible case of transfusion associated graft versus host disease.](#) *BMJ.* 2022.

*Contributed by Richard Gammon, MD, Medical Director at OneBlood* 💧



### ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



America's Blood Centers®  
It's About *Life*.

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.*

### December *Blood Bulletin* Published

America's Blood Center's (ABC) has published the December 2022 edition of the [Blood Bulletin](#). The issue is titled "To Wash Blood Components or Not — Indications and Alternatives" and ([PDF](#) or [MS Word](#) versions) of the [Blood Bulletin](#) are available. The article was written by Nancy Van Buren, MD, Medical Director at Innovative Blood Resources and Community Blood Center of Kansas City, divisions of New York Blood Center; Nanci Fredrich, RN, BSN, MM, Transfusion Safety Officer at Versiti; Richard Gammon, MD, Medical Director at OneBlood; Debra Smith, MD, PhD, Medical Director at Carter BloodCare; Ruchika Goel, MD, MPH, Medical Director at ImpactLife; Louis Katz, MD, Chief Medical Officer Emeritus at ImpactLife; Claudia S. Cohn, MD, PhD, Professor of Laboratory Medicine and Pathology at the University of Minnesota. [Blood Bulletin](#) is reviewed and edited by ABC's SMT Publications Committee.

(Source: [MCN 22-101](#), 12/22/22)

### Executive Compensation Survey Report Available

America's Blood Centers' (ABC) annual Executive Compensation Survey report has been published. The survey is a benchmarking tool for executive leadership and human resources professionals at ABC member blood centers that features aggregate data on salaries and benefits for C-suite leadership. As with all ABC surveys, data is strictly confidential and anonymized. Members who participated in the survey should have received the link to view the results via email this week. If you have not received your copy, contact [us](#). Information on all ABC benchmarking surveys can be found [here](#).

### Television & Radio Versions of "Career in Blood" Recruitment Video Available

Television and radio versions of the "Career in Blood" recruitment video are now [available](#) to members in the form of 30 and 60 second ads for both mediums. Last month, America's Blood Centers (ABC) announced the development of the "[Career in Blood](#)" recruitment video to assist member blood centers in attracting a diverse pool of jobseekers in the face of workplace shortages impacting industries across the country. This member-exclusive customizable resource is available in both English and Spanish with male and female narration and can be used on websites and social media channels. Whether jobseekers are hoping to transfer their existing skills or are looking for an entry level position with on-the-job training, an opportunity is available at a community blood center. The video highlights how the blood center team includes phlebotomists, communications and marketing staff, laboratory professionals, and more, all focused on a single mission: the lifesaving power of blood donation. ABC continues to seek ideas for similar videos that would assist blood centers in their hiring. Please contact ABC Director of Strategic Communications and National Partnerships [Jeff Gohringer](#) with questions or concepts that would help you attract and retain staff.

(Source: ABC Announcement, 12/9/22) 💧



## PEOPLE



**Rick Axelrod, MD, MBA**, president, chief executive officer, and medical director of LifeStream Blood Bank will retire on June 20<sup>th</sup>. “Dr. Axelrod joined the organization in June 2004 when it was then known as Blood Bank of San Bernardino and Riverside Counties with 275 employees serving 33 hospitals in two counties. During his tenure, the organization has grown to include 425 employees serving 80 hospitals in six counties, added five blood donation and two distribution centers, doubled the volume of its reference laboratory business and added new programs for stimulated granulocytes, stem cell and dendreon collections, and a therapeutic apheresis program serving patients in the entire Southern California region. During his 19-year career at the blood center, Dr. Axelrod has been a vital part of the blood community at both the local and national levels including serving as the primary voting industry representative for the Dept. of Health and Human Services Advisory Committee for Blood Safety and Availability, vice president, secretary and treasurer, board of directors, America’s Blood Centers (ABC) and Secretary, board of directors, Blood Centers of California. Locally, Dr. Axelrod has served as Chairman, board of directors for Desert Regional Medical Center, Chairman, board of directors, Coachella Valley Economic Partnership and Member, board of directors, Greater Palm Springs Convention and Visitors Bureau. In 2017, Dr. Axelrod received the Spirit of the Entrepreneur Award from California State University, San Bernardino as non-profit executive of the year. He received his medical degree from Emory University School of Medicine, where he also completed his residency in anatomic and clinical pathology. He completed his fellowship in transfusion medicine at Cedars-Sinai Medical Center and received his MBA from the Kellogg School of Management at Northwestern University. Dr. Axelrod plans to continue to work as a medical director in the southern California area.”

(Source: LifeStream Announcement, 1/4/23) 💧

## BRIEFLY NOTED

**The U.S. Health Resources and Services Administration’s (HRSA) Health Systems Bureau, Division of Transplantation (DoT) is “soliciting” [requests](#) from “non-federal public and private sector organizations and entities who wish to collaborate on the DoNation Campaign.”** A notice appearing in the *Federal Register* explains that “DoNation collaboration projects will involve executing a series of activities that elevate the benefits and importance of organ, eye, and tissue donation and increase organ donor registrations among the public with a focus on individuals from diverse racial and ethnic backgrounds. Potential collaborating organizations must have demonstrated interest in and experience with coordinating activities that address key public health issues, be capable of managing the day-to-day operations associated with the proposed activity(ies), and be willing to participate substantively in the execution of the proposed activity(ies), not just providing funding or logistical support.” Requests must be received via email or mail by January 31<sup>st</sup>.

(Source: *Federal Register* [Notice](#), 1/6/22)

**Secure Transfusion Solutions (STS) has received [approval](#) of its biologics license application (BLA) from the U.S. Food and Drug Administration (FDA) for “interstate distribution of pathogen reduced apheresis platelets from its Trusting Heart Blood Center located in Edina, Minn.”** STS is the parent organization of Trusting Heart Blood Center whose donor centers financially compensate platelet donors.”

(Source: STS [News Release](#), 1/3/23) 💧



## COMPANY NEWS

**Vascarta Inc.** and the U.S. Food and Drug Administration (FDA) are collaborating on research to “study the pharmacodynamic properties of the topical/transdermal drug candidate [VASCEPTOR™] on aged human blood cells through *in vitro* analysis.” According to Vascarta, the project aims to “increase the shelf life and quality profile of refrigerated human blood which is potentially of huge impact to the field of transfusion medicine.”

(Source: Vascarta Inc. Announcement, 12/12/22) 💧

## CALENDAR

*Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org). (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

### 2023

Mar. 6-8. **ABC Annual Meeting, Washington, D.C.** [Registration](#) is open. Additional information is available [here](#).

April. 24-28. **ABC Blood Advocacy Week.** More information coming soon.

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** [Registration](#) is open. Additional information is available [here](#).

May 10-11. **29<sup>th</sup> IPFA/ Paul-Ehrlich-Institut[e] (PEI) International Workshop on Surveillance and Screening of Blood-borne Pathogens, Bologna, Italy.** More information available [here](#).

Sept. 17-20. **American Association of Tissue Banks Annual Meeting, National Harbor, Md.** More information available [here](#).

Oct. 9-11. **Advanced Medical Technology Association (AdvaMed) The MedTech Conference, Anaheim, Calif.** More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** More information available [here](#). 💧

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## POSITIONS

**President and CEO.** LifeStream Blood Bank, headquartered in San Bernardino, California, an independent blood center serving 80 hospitals in six counties in Southern California is seeking a President and CEO to lead the organization. Reporting to the Chair, Board of Directors, the preferred candidate is one who has demonstrated successful leadership in other blood centers or healthcare related organizations. The successful candidate must possess strong strategic planning skills to navigate a competitive environment and strong interpersonal and communication skills to develop strong relationships in the community and within the organization. Primary emphasis for this position is to ensure effective beneficial business/service affiliations, strong community supported blood donor collections, loyal employee relations,

solid asset management and ongoing financial stability. The candidate must have at least five years’ experience serving as an executive team member (reporting to CEO) and/or CEO for a blood center or healthcare organization and hold a bachelor’s degree from an accredited college or university. A graduate degree such as MBA, MHA, MPH or equivalent is preferred. Competitive salary, relocation package and excellent benefits. Please submit cover letter, resume and salary requirements to Judy Taylor, Director, Human Resources at [taylorju@lstream.org](mailto:taylorju@lstream.org). The deadline for applications is **February 3, 2023**.

(continued on page 9)



## POSITIONS (continued from page 8)

**Director, Marketing and Public Relations.** LifeStream, a local nonprofit organization providing blood services for more than 80 hospitals in Southern California, is searching for a Director, Marketing and Public Relations. Reporting to the Vice President, Operations, and managing a staff of four employees, the Director of Marketing and Public Relations is responsible for developing and implementing marketing and communication strategies to ensure daily, monthly, and annual collection targets are achieved. Also responsible for account planning, staffing (marketing and creative resources), and oversight of all day-to-day marketing and public relations activities to ensure quality work is being achieved and delivered. This individual will monitor the effectiveness of marketing efforts, including; campaigns, promotions, special events, and communications with internal and external key stakeholders. Takes proactive steps when results are not meeting organizational needs. This position works closely with multiple departments to ensure successful market delivery. The ideal candidate will possess a bachelor's degree (BA) in Marketing, Advertising, Business, Communications, Public Affairs, or a related field. Three to five years' work experience and a minimum of one year management experience in marketing and/or public relations. Demonstrated strategic thinking and analytical skills to help set marketing agendas. Apply online: [www.LStream.org](http://www.LStream.org). E-mail: [recruitment@LStream.org](mailto:recruitment@LStream.org). EOE.

**Technical Manager.** LifeSouth Community Blood Centers is seeking a full time certified Medical Laboratory Technician (MLT) with experience in transfusion services for our Mobile, AL center. This position is responsible for managing production through subordinator coordinators and staff. The selected candidate will also be fully accountable for costs, methods, personnel, quality, inventory and distribution within the Components Laboratory and Hospital Services departments. The applicant should be knowledgeable of FDA and AABB standards and other regulatory requirements, have strong planning and process management skills. Visit our [careers page](#) to learn more about us and apply.

**Regional Manager.** LifeSouth Community Blood Centers is seeking a full time Regional Manager in McDonough, GA. This position is responsible for overseeing daily operations of the region to ensure daily and long-range commitments of the blood bank are met. This includes overseeing blood collection, donor recruitment, components production, blood labeling and blood distribution in assigned region. Minimum qualifications include a bachelor's degree in a related field, three years of relevant management experience, knowledge of general budgeting, accounting, and personnel management techniques. Visit our [careers page](#) to learn more about us and apply.

**Chief Medical Officer.** America's Blood Centers (ABC), North America's largest network of community based, independent blood programs, is seeking a **Chief Medical Officer.** Reporting to the Chief Executive Officer (CEO), the Chief Medical Officer (CMO) is responsible for implementing strategies and tactics, consistent with the best scientific and medical evidence and regulatory requirements, that support America's Blood Centers' (ABC) mission, maintain our values, and realize our vision. The CMO works as part of the ABC Senior Executive Team (SET) to communicate ABC's issues to members, regulators, legislators, the media, and external groups and mobilizes ABC members and professional staff to achieve the strategic goals of the organization. Primary Responsibilities: Represent independent nonprofit community blood centers on scientific, medical, and technical matters as well as donor and patient safety concerns before federal agencies, industry, and other business partners, allied domestic and international organizations, scientific societies, the media, and the public. Education & Experience: Medical Degree required. U.S. medical license required with board certification in a medical specialty. Board certification in pathology, transfusion medicine, hematology, or infectious disease preferred. Ten or more years' experience related to blood banking or transfusion medicine. Three or more years' experience with healthcare and/or blood banking issues at a national level via committee work, offices held, or other appropriate experience. Administrative experience in a leadership role preferred. Work Environment and Conditions: This position is a consultant with an expected 40-60 hours per month. Additional time may be required (and paid) for travel. The CMO office may be located anywhere in the United States with travel to the ABC Washington, DC office as required and domestic travel on behalf of ABC to ABC meetings, to interact with government decision makers, and to liaison with external organizations as assigned. Click [here](#) to view the full job description. Interested applicants should send a cover letter and resume to [careers@americasblood.org](mailto:careers@americasblood.org).

**Director of Finance.** LifeSouth Community Blood Centers is seeking an experienced CPA as our Director of Finance. The Director is responsible for ensuring the stability of LifeSouth's finances through planning, directing, and controlling financial functions, including establishing appropriate control environments, preparing financial reports for management, financial analysis, overseeing development and implementation of effective financial and accounting systems. This position oversees all staff in the Accounting and Purchasing departments. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our [careers page](#) to learn more about us and apply.

(continued on page 10)

## POSITIONS (continued from page 9)

### **Medical Technologist – 2nd Shift or 3rd Shift.**

LifeSouth Community Blood Centers is seeking Medical Technologists to perform specialized lab testing for cellular therapies and lab testing for the quality control of cellular therapies and blood components. Additional responsibilities include performing specialized lab testing for RBC and HPA genotyping, HLA typing and HLA and HPA antibody identification, perform DNA extraction and adhere to clinical laboratory's quality control policies. The individual will have a bachelor's in Clinical Lab, Chemical or Biological Science and a current Florida Medical Technologist license. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our [careers page](#) to learn more about us and apply.

**Compensation and Benefits Manager.** LifeSouth Community Blood Centers is seeking an experienced Compensation and Benefits Manager to join our Human Resources team at our headquarters in Gainesville, FL. This position is responsible for facilitating the organization's compensation and benefits programs as well as providing strategic leadership for its administration, including enrollment, maintenance, and compliance with regulations. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our [careers page](#) to learn more about us and apply.

**Laboratory Technologist.** LifeSouth Community Blood Centers is seeking a skilled Laboratory Technologist in our immunoematology Reference Laboratory in Atlanta, Georgia. The position is a full-time evening shift with the option of working 4-10 hour shifts or 5-8 hour shifts per week. The candidate for this position must be able to work independently, communicate effectively and can perform and interpret clinical laboratory tests for providing blood for a patient in need of a transfusion. This position requires extensive understanding of blood group serology, compatibility testing and selection of blood for a patient in need of a transfusion. This position requires extensive understanding of blood group serology, compatibility testing, and selection of blood for patients with complex serological problems. Visit our [careers page](#) to learn more about us and apply.

**Public Relations Manager (Oklahoma City, Okla.).** Oklahoma Blood Institute is seeking a **Public Relations Manager** to direct earned media efforts for the organization, to promote and increase lifesaving blood donation. The PR Manager, who will be reporting to the Associate Vice President of Recruitment Operations, will be responsible for strategy, execution, and evaluation of public relations campaigns, to help tell the organization's story to key audiences. Qualifications: Bachelor's degree required, five plus years' experience in public relations, media or related field, some travel required, must excel

in both narrative and journalistic style with a firm knowledge of AP style, ability to showcase the organizations mission and work, and must understand media outlet habits and channel-specific needs. Salary Range: Competitive salary with excellent benefits package including health, dental, vision, and life insurance, long term disability, 401(k), paid time off, annual tuition reimbursement, generous retention bonus', and holiday pay. Please apply on our [website only](#) at <http://obi.org/careers/>

**Medical & Laboratory Director – West Division.** Vitalant is currently seeking a Medical & Laboratory Director to provide oversight for the patients, donors, staff, and healthcare professionals in our West Division (CA and WA). Routine duties include blood center activities such as component manufacturing, product management, laboratory testing, donor suitability and counseling, education, & consultation and clinical services activities such as oversight of an immunoematology reference laboratory, transfusion services, therapeutic apheresis, and cellular therapy collections (e.g., Dendreon). Additional areas of specialization, such as cell sourcing and cellular therapy/cord blood, may be assigned as needed. This position works directly with the Corporate and Division teams to promote Vitalant's mission, vision, quality policy, and strategic initiatives to position Vitalant as a Center of Transfusion Medicine Excellence. Modeling high ethical, customer care, and confidentiality standards always, this person serves a vital role for assuring compliance with current policies, programs, and directives and providing medical support for the Blood Services Division and Vitalant Clinical Services. This role can work remotely anywhere within the West Division (California or Washington) with 20 percent travel to visit internal and external partners. How to apply: <https://bloodsystems.taleo.net/careersection/jobdetail.ftl?job=223087&lang=en>

**Manager of Donor Resources.** The Blood Connection is seeking a Manager of Donor Resources in Charlotte, N.C. and Greenville, SC to provide oversight to our recruitment teams within these divisions. This position directs Account Managers and Business Development Representatives to strategically manage our existing portfolio of blood donor groups and new business to reach collection targets. The Manager of Donor Resources monitors progress to goal proactively and effectively coaches and manages the team to success. The ideal candidate will have a strong background in territory management and team building. Candidates must possess excellent interpersonal, analytical, and strategic planning abilities. We offer an exceptional benefits package including a generous 401k match, 30 days PTO, company bonuses, tuition reimbursement, cell phone stipend, and yearly increases. Join one of the fastest growing blood centers in the coun

(continued on page 11)

POSITIONS (continued from page 10)

try and help make an impact in your community today!  
How to apply: [Manager of Donor Resources Application](#)

**Cellular Therapy/Transfusion Medicine Specialist.**

The Department of Laboratory Medicine is seeking a Clinical Pathology and Transfusion Medicine and/or Hematopathology specialist for a faculty position at the Benioff Children's Hospital in Oakland (BCH-Oak), CA. The successful candidate will work with the other Medical Directors at the other UCSF sites to implement the academic mission of the UCSF Clinical Pathology service, which includes training of residents and fellows. The successful candidate will be part of a team of Pathologists working in the BCH-Oak Clinical Laboratories. Candidates must be board certified/board eligible in Clinical Pathology and have completed a Blood Banking /Transfusion Medicine and/or Hematopathology fellowship. Applicants who have expertise in these fields are encouraged to apply. Candidates with interest and/or research experience in Cellular Therapies are preferred. Candidates must be eligible for a California Medical license. For more information and to apply please submit a curriculum vitae, a cover letter outlining your interests and experience, a statement of contributions to diversity, and the names of three (3) references (in confidence) to <https://apptrkr.com/3715610>. 💧